Dermata Therapeutics, Inc.
DRMAHealthcare|Biotechnology|US
$0.76
+0.00 (+0.28%)
DCF Value
$7.66
Tangible Book / Share
$0.87
Cash / Share
$1.10
About
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Stock Price
-74.1%(1Y)
1M
-28.6%
3M
-30.5%
6M
-39.4%
YTD
-67.1%
1Y
-76.3%
3Y
-99.3%
5Y
-100.0%
Pipeline Summary
6 total trials0
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
Completed: 5Unknown: 1
Key Facts
Market Cap$3.8M
Employees9 (+13% YoY)
CEOGerald T. Proehl
IPO DateAug 13, 2021
Beta0.63
52-Week Range$0.603 – $4.66
Avg Volume530,132
ExchangeNASDAQ
Websitedermatarx.com
Ownership
Float57.7%
Shares Outstanding5.0M
Recent Insider Trades
PROEHL GERALD TAWARD
Aug 16, 20261,360,544 shares @ $0.00
PROEHL GERALD TAWARD
Aug 16, 20261,360,544 shares @ $1.47
PROEHL GERALD TAWARD
Aug 16, 20261,360,544 shares @ $1.47
PROEHL GERALD TAWARD
Aug 16, 2026170,068 shares
PROEHL GERALD TAWARD
Aug 16, 2026170,068 shares @ $1.47
Peers
Recent News
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
Oct 15, 2026 · accessnewswire.com
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
Aug 25, 2026 · accessnewswire.com
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
Aug 21, 2026 · accessnewswire.com
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aug 17, 2026 · accessnewswire.com
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Aug 11, 2026 · accessnewswire.com
Data last updated: Nov 9, 2026, 04:06 AM